Latest action: Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 464.
Bill is filed in its originating chamber and assigned a number.
Sponsor
Christopher Smith (R-NJ)
Filed in the House.
Next: In Committee
Members of the committee(s) the bill was referred to
Reauthorizes federal funding and oversight for stem cell research and therapeutic development programs.
The problem
Previous stem cell research authorization expired or requires renewal. Scientists and medical researchers need clear federal funding and regulatory framework to continue work.
The proposal
The bill extends federal authority and funding mechanisms for stem cell research, including therapeutic applications and scientific studies using stem cell technology.
The impact
Medical researchers, biotech companies, and patients with diseases potentially treatable by stem cell therapy are affected by funding availability and regulatory clarity.
Continued stem cell research may lead to treatments for diseases like Parkinson's, diabetes, and spinal cord injuries. Federal funding supports labs and scientists working on breakthrough therapies.
Biotech and pharmaceutical companies can invest in stem cell therapies and products. This creates jobs and positions the U.S. competitively in the global biotech market.
Clear federal authorization provides certainty for researchers and companies. They can plan long-term projects without worrying about sudden funding or authorization changes.
Patients with currently untreatable diseases may benefit from new therapies. Continued research keeps hope alive for future cures and treatments.
Some people have moral objections to stem cell research, particularly regarding embryonic stem cells. The bill may fund research that conflicts with certain religious or philosophical beliefs.
The bill authorizes government funding for stem cell research. Critics argue these funds could be used for other priorities or worry about long-term budget commitments.
While promising, many stem cell therapies remain experimental with uncertain timelines for approval. Funding may support research that never becomes practical treatments.
Some argue private companies should fund stem cell research rather than taxpayers. Federal funding may crowd out private investment or create unfair advantages.
Generated by AI from the bill text. Not a prediction and not legal or policy advice. The percentage is the model's own rating of each item — self-reported, and not a measure of how accurate it is.
Loading map…
Loading...
0 citizens have already voted
Free · No spam · See how your representatives voted
Be the first to weigh in
Your vote starts the conversation
How citizen engagement works
Citizens vote & comment
Public opinion data is aggregated and updated in real time.
Patterns become visible
Representatives can see constituent sentiment broken down by district.
Your voice on the record
Contact your rep directly — one constituent call can shift a staffer's priority list.
Research shows that constituent contacts — especially calls — are among the most effective ways to influence a legislator's position on active bills.
Individual contributions, grouped by employer · FEC
Where their individual donors work · 2026 cycle
Money from people who work there, not from the company. Not tied to this bill.
Itemized individual contributions via FEC, grouped by the employer each contributor self-reported. Companies and unions cannot contribute to federal candidates from their treasuries, so these totals are money from people who work at an employer — never from the organization itself. They are campaign contributions covering a full election cycle and are not connected to this bill.
Senate LDA lobbying disclosures
Couldn't load lobbying disclosures right now.